Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ali Golchin has a total of 156 co-authors. Here are the top co-authors by number of shared publications:

  • Parviz Ranjbarvan

    Department of Applied Cell Sciences, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

    12 shared publications
  • Abdolreza Ardeshirylajimi

    Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    8 shared publications
  • Arezo Azari

    School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

    6 shared publications
  • Forough Shams

    Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    6 shared publications
  • Maryam Rahnama

    Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

    6 shared publications
  • Simzar Hosseinzadeh

    Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    5 shared publications

Latest Publications

  • Open Access

    Role of Ferroptosis in Diabetic Foot Ulcers: Pathophysiological Mechanisms, Biomarkers, and Therapeutic Potencies

    by Amirreza Alikhani, Faezeh Faalbin, Arezo Azari, Aynaz Mihanfar, Ali Golchin

    Diabetic foot ulcer (DFU) is one of the major complications of diabetes mellitus and often results in persistent non-healing lesions, infections, and amputations. Recently, an iron-dependent form of programmed cell death, ferroptosis, has been shown to have an essential role in the poor regeneration of DFUs. This mini-review aims to study the role of ferroptosis in the pathophysiology of diabetic wounds, clinical biomarkers, and potential treatments by targeting ferroptotic pathways. Hence, PubMed-indexed studies on ferroptosis in relation to diabetic wound healing, including in vitro , animal, and clinical studies, were systematically reviewed. The research was evaluated based on molecular mechanisms, biomarkers, and preclinical and clinical evidence. Ferroptosis inhibits wound healing by promoting lipid peroxidation, oxidative stress, and cell death in fibroblasts, keratinocytes, and endothelial cells. Wound severity and healing are associated with tissue and circulation biomarkers such as Glutathione Peroxidase 4 (GPX4), Solute Carrier Family 7 Member 11 (SLC7A11), Acyl-CoA Synthetase Long-Chain Family Member 4 (ACSL4), Malondialdehyde (MDA), and 4-Hydroxynonenal (4-HNE). Several treatments, including small-molecule ferroptosis inhibitors, iron chelators, and extracellular vesicles from mesenchymal stem cells, have demonstrated therapeutic benefits in preclinical studies ( in vitro and animal models) and early-phase clinical assessments, although no randomized controlled trials are currently available. Inhibition of ferroptosis is a promising and rational therapeutic approach to improve DFU healing. It is essential to normalize these biomarkers, optimize therapeutic regimens, and perform extensive, robust clinical trials to translate the preclinical findings for chronic diabetic wounds into effective patient treatments.

  • Platelet Rich Plasma for Wound Healing: Evidence from Veterinary Regenerative Medicine

    by Merlin Mamachan, Shajahan Amitha Banu, Sathish Muthu, Ali Golchin, Khan Sharun

  • Heat shock proteins in sperm capacitation: A functional perspective

    by Aynaz Mihanfar, Mohammed Kareem Mutsher, Forough Shams, Ali Mohammad Amani, Navid Ghasemzadeh, Maryam Rahnama, Ali Golchin

  • Menstrual Blood Stem Cell-Derived Exosomes as Modulators of Apoptosis, Migration and Angiogenesis in Breast Cancer Cells

    by Navid Ghasemzadeh, Ali Golchin, Zeinab Latifi, Shahriar Alipour, Fatemeh Kheradmand

    The complexity of breast cancer cells complicates the process of enhancing our understanding, which may lead to the development of effective therapeutic agents and approaches. Among the novel medical interventions, menstrual blood-derived mesenchymal stem cells (Mens-MSCs) demonstrate proactive and immunomodulatory interactions with malignant cells. This study aims to evaluate the effects of Mens-MSCs-derived exosomes (MM-Exos) on breast cancer cell behaviors, with particular emphasis on apoptosis, migration, and angiogenesis. MM-Exos were characterized using DLS, flow cytometry, and TEM. After determining the effective concentration by MTT assay, the exosomes were applied to MDA-MB-231 and SK-BR-3 cell lines. Cell motility was evaluated using a scratch assay, while apoptosis, cell cycle distribution, and ROS generation were assessed by flow cytometry and ELISA. Gene expression of BAX, BCL-2, MMP-2, and VEGF was analyzed by qPCR, and corresponding protein levels were confirmed through Western blotting. Based on the results, MM-Exos dose-dependently decreased breast cancer cell survival across both cell lines. Furthermore, MM-Exos at 50 and 100 µg/ml significantly reduced the migratory rate of cell lines (P < 0.001). Treatment with MM-Exos (100 µg/ml) significantly increased ROS production (P < 0.001), enhanced apoptosis (P < 0.001), induced cell cycle arrest (P < 0.001), and altered gene and protein expression. Both cell lines exhibited significant down-regulation of VEGF(P < 0.001), BCL-2 (P < 0.01), and MMP-2 (P < 0.01) after treatment with MM-Exos, whereas BAX demonstrated significant up-regulation (P < 0.001). Based on results, MM-Exo demonstrates anticancer functions by enhancing cytotoxicity, ROS generation, apoptosis, while reducing migration rate. Thus, MM-Exo may represent a potential therapeutic option for breast cancer; however, further comprehensive studies are required.

  • The Potential of Menstrual Blood-Derived Extracellular Vesicles (MenMSC-Evs) in Combination with Platelet-Rich Fibrin (PRF) as a Biological Adjuvant for Improving Full-Thickness Wound Healing

    by Maryam Rahnama, Fariba Abbasi, Parviz Ranjbarvan, Ali Golchin

    Full-thickness wound healing, particularly in chronic wounds, has remained a significant clinical challenge due to limited regenerative therapies and immune responses. Although the different biologic-based combination therapies have been suggested, the effective and safe biological adjuvants require further research and development to optimize their potential for wound healing. This study investigates the synergistic effect of menstrual blood mesenchymal stem cell-derived extracellular vesicles (MenMSC-Evs) combined with platelet-rich fibrin (PRF) on full-thickness wound healing. In this context, the MenMSC-Evs and PRF were first assessed in vitro (n = 3) for their antibacterial efficacy against E. coli, S. aureus, and P. aeruginosa. The impact of MenMSC-Evs on the proliferation and migration of HUVECs and NIH3T3 cells was evaluated to determine their influence on cellular behaviors. In vivo, a full-thickness excisional wound model was established on nine Wistar rats, with four wounds per rat assigned to different treatment groups, to evaluate wound healing. In vitro, MenMSC-Evs significantly enhanced the proliferation and migration of HUVECs by 29.3% and 11.5%, respectively, and NIH3T3 cells by 24.7% and 8.5% (p < 0.01, p < 0.001). PRF-Evs also demonstrated improved antibacterial activity, particularly against S. aureus (p < 0.001). In vivo, PRF-Evs accelerated wound closure by 23.2% (p < 0.001), increased collagen deposition (p < 0.001), and promoted angiogenesis, as evidenced by a 1.9-fold increase in VEGF-A expression and a 3.1-fold rise in CD34-positive microvessel density (p < 0.001). Moreover, PRF-Evs modulated macrophage polarization by reducing pro-inflammatory cytokines—IL-1β (8.2-fold) and TNF-α (4.4-fold)—while upregulating anti-inflammatory cytokines, including IL-10 (3.2-fold) and TGF-β (2.7-fold) (p < 0.001). In conclusion, these findings indicate that the novel combination of MenMSC-Evs and PRF offers a promising cell-free therapeutic strategy for chronic wound management by enhancing immunomodulation, promoting neovascularization, and facilitating tissue regeneration. Graphical Abstract Schematic overview of Evs isolation from MenMSCs and integration with PRF for wound healing. a) PRF was extracted from venous blood and subsequently freeze-dried. b) Evs were extracted from MenMSCs and seeded onto a PRF. c) Characterization of the Evs was performed using DLS, TEM, flow cytometry, and protein assays, while the PRF-Evs complex was analyzed via FE-SEM. d) In vitro assays evaluated the effects of MenMSC-Evs on the proliferation and viability of HUVEC and NIH3T3 fibroblast cell lines, alongside antibacterial assessments of PRF, MenMSC-Evs, and PRF-Evs complexes against E. coli, S. aureus, and P. aeruginosa. e)The therapeutic efficacy of PRF, MenMSC-Evs, and PRF-Evs complexes on wound healing in Wistar rats was analyzed through metrics including wound closure dynamics, histopathological evaluations (H&E staining), angiogenesis (CD34 and VEGF-A), collagen deposition (Masson's trichrome staining, collagen I, and collagen III assessments), and macrophage polarization (CD68 expression and cytokines assay). (Abbreviations: MenMSCs: menstrual-derived mesenchymal stem cells, PRF: platelet-rich fibrin, PRF-Evs, platelet-rich fibrin loaded with Evs, DLS: dynamic light scattering, TEM: transmission electron microscopy, FE-SEM: field emission scanning electron microscopy, HUVEC: human umbilical vein endothelial cells)


  • Open Access

    Tissue Engineering in Cosmetics and Dermatology: A New Era of Innovation and Application

    by Ali Golchin, Maryam Rahnama, Mohammad Saleh Chapani, Forough Shams, Mahmood Rekabgardan, Zahra Poursalehi, Parviz Ranjbarvan

    The convergence of tissue engineering and the cosmetic industry marks a transformative axis in the development of advanced cosmetic products and therapies. The current study explores the recent landscape and future potential of applying tissue engineering techniques within the cosmetic industry. The study highlights key innovations, such as the development of lab-grown skin for product testing and personalized skin grafts for aesthetic enhancements, which not only promise to enhance product efficacy and safety but also offer sustainable and ethical alternatives to traditional methods reliant on animal testing. This study reviews scientific progress in biomaterials, scaffold design, and cellular manipulation that promote skin tissue regeneration and repair, wound healing, breast implants, and oral care, highlighting the capacity to tackle intricate aesthetic issues such as scarring, skin aging, and pigmentation disorders. The ethical, regulatory, and economic implications of integrating tissue engineering into cosmetics are also discussed, providing a comprehensive overview of the challenges and opportunities facing this burgeoning field. By advancing the capabilities of cosmetic applications, tissue engineering not only pioneers innovative solutions for personalized beauty care and dermatology but also sets a precedent for future interdisciplinary collaborations in cosmetic science.


  • Menstrual blood and endometrial mesenchymal stem/stromal cells: A frontier in regenerative medicine and cancer therapy

    by Maryam Rahnama, Navid Ghasemzadeh, Zeinab Latifi, Fatemeh Kheradmand, Fariba Abbasi Koukia, Khan Sharun, Ali Golchin


  • Single-cell Technology in Stem Cell Research

    by Ali Golchin, Forough Shams, Faezeh Moradi, Amin Ebrahimi Sadrabadi, Shima Parviz, Shahriar Alipour, Parviz Ranjbarvan, Yaser Hemmati, Maryam Rahnama, Yousef Rasmi, et al.

    Single-cell technology (SCT), which enables the examination of the fundamental units comprising biological organs, tissues, and cells, has emerged as a powerful tool, particularly in the field of biology, with a profound impact on stem cell research. This innovative technology opens new pathways for acquiring cell-specific data and gaining insights into the molecular pathways governing organ function and biology. SCT is not only frequently used to explore rare and diverse cell types, including stem cells, but it also unveils the intricacies of cellular diversity and dynamics. This perspective, crucial for advancing stem cell research, facilitates non-invasive analyses of molecular dynamics and cellular functions over time. Despite numerous investigations into potential stem cell therapies for genetic disorders, degenerative conditions, and severe injuries, the number of approved stem cell-based treatments remains limited. This limitation is attributed to the various heterogeneities present among stem cell sources, hindering their widespread clinical utilization. Furthermore, stem cell research is intimately connected with cutting-edge technologies, such as microfluidic organoids, CRISPR technology, and cell/tissue engineering. Each strategy developed to overcome the constraints of stem cell research has the potential to significantly impact advanced stem cell therapies. Drawing on the advantages and progress achieved through SCT-based approaches, this study aims to provide an overview of the advancements and concepts associated with the utilization of SCT in stem cell research and its related fields.